GTB-3550 Tri-Specific Killer Engager (TriKE)

GTB-3550 Tri-Specific Killer Engager (TriKE) · GT Biopharma, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GTB-3550 Tri-Specific Killer Engager (TriKE), covering 2022-11-10 to 2022-11-10. Get the full timeline:

Most recent: Clinical Trial Update: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies [Phase 1, Phase 2]